Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Correlation Between the Presence of BRAFV600E and TERT Promoter Mutation and the Response to Treatment with Iodine 131 in Differentiated Thyroid Cancer Patients.

Genes - 31 May 2026

Granić Roko, Blažeković Ivan, Miš Josipa, Šamija Ivan, Džombeta Tihana Regović, Mirošević Gorana, Bakunić Denis, Kralik Kristina, Fröbe Ana, Kusić Zvonko, Jukić Tomislav

Abstract excerpt

Objectives: The response to radioiodine therapy (RAI) in differentiated thyroid cancer (DTC) patients is one of the most important factors that determines the treatment outcome and overall prognosis. The objective of this study is to determine the correlation between BRAFV600E and TERT promoter (TERTp) mutation in tumor samples of DTC patients with the response to RAI as well as correlation with clinical and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Iodine Radioisotopes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Prognosis

Share to Promoter Regions, Genetic

Share to Proto-Oncogene Proteins B-raf

Share to Telomerase

Share to Thyroid Neoplasms

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 42353802
DOI: 10.3390/genes17060645
PMCID: PMC13299577

Genes

TERT
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Correlation Between the Presence of BRAFV600E and TERT Promoter Mutation and the Response to Treatment with Iodine 131 in Differentiated Thyroid Cancer Patients.PMID 42353802Read ↗

Effect of BRAFV600E and TERT Promoter Mutations on Thyroglobulin Response in Patients With Distant-Metastatic Differentiated Thyroid Cancer.Semantic proximity Read ↗

TERT Promoter Mutations Contribute to Adverse Clinical Outcomes and Poor Prognosis in Radioiodine Refractory Differentiated Thyroid CancerSemantic proximity Read ↗

TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer.Semantic proximity Read ↗

TERT promoter mutations contribute to adverse clinical outcomes and poor prognosis in radioiodine refractory differentiated thyroid cancer.Semantic proximity Read ↗

Impact of BRAF V600E and TERT Promoter Mutations on Response to Therapy in Papillary Thyroid CancerSemantic proximity Read ↗

TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease.Semantic proximity Read ↗

Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.Semantic proximity Read ↗

Association between clinical and pathological factors and risk of radioiodine refractory in patients with differentiated thyroid carcinoma.Semantic proximity Read ↗

Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients.Semantic proximity Read ↗

Evaluation of BRAF V600E and TERT mutation analysis in differential thyroid cancers.Semantic proximity Read ↗

How do BRAFV600E and TERT promoter mutations interact with the ATA and TNM staging systems in thyroid cancer?Semantic proximity Read ↗

TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.